2EM Stock Overview
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Ergomed plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£11.00 |
| 52 Week High | UK£16.10 |
| 52 Week Low | UK£11.00 |
| Beta | 0.86 |
| 11 Month Change | 0% |
| 3 Month Change | -3.85% |
| 1 Year Change | -5.98% |
| 33 Year Change | 113.18% |
| 5 Year Change | 461.22% |
| Change since IPO | 349.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2EM | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.9% | 0.8% |
| 1Y | -6.0% | 5.4% | 9.1% |
Return vs Industry: 2EM exceeded the German Life Sciences industry which returned -23.6% over the past year.
Return vs Market: 2EM underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| 2EM volatility | |
|---|---|
| 2EM Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2EM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2EM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 1,400 | n/a | www.ergomedplc.com |
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies.
Ergomed plc Fundamentals Summary
| 2EM fundamental statistics | |
|---|---|
| Market cap | €567.10m |
| Earnings (TTM) | €17.43m |
| Revenue (TTM) | €169.00m |
32.5x
P/E Ratio3.4x
P/S RatioIs 2EM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2EM income statement (TTM) | |
|---|---|
| Revenue | UK£145.26m |
| Cost of Revenue | UK£64.71m |
| Gross Profit | UK£80.55m |
| Other Expenses | UK£65.57m |
| Earnings | UK£14.98m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.30 |
| Gross Margin | 55.45% |
| Net Profit Margin | 10.31% |
| Debt/Equity Ratio | 0% |
How did 2EM perform over the long term?
See historical performance and comparison